Vibegron Does Not Cause Hypotension
Vibegron (GEMTESA) is not associated with clinically significant hypotension. According to the FDA drug label, a 4-week randomized, placebo-controlled ambulatory blood pressure study in 200 OAB patients demonstrated that daily treatment with vibegron 75 mg was not associated with clinically significant changes in blood pressure 1.
Key Evidence from FDA Label and Clinical Studies
The FDA-approved labeling explicitly addresses blood pressure effects in the pharmacodynamics section. In the pivotal ambulatory blood pressure monitoring study:
- Patient population: Mean age 59 years, 75% female
- Baseline hypertension: 35% had pre-existing hypertension, 29% were taking concomitant antihypertensive medications
- Result: No clinically significant changes in blood pressure with vibegron 75 mg daily 1
Mechanism and Selectivity
Vibegron is a selective β3-adrenergic receptor agonist that works by relaxing detrusor smooth muscle during bladder filling 1. Unlike β-blockers (which can cause hypotension, especially those with alpha-1 receptor blocking properties like carvedilol 2, 3, 2), vibegron's selective β3-agonism does not produce vasodilatory effects that would lead to hypotension.
Supporting Research Evidence
Multiple clinical trials confirm the cardiovascular safety profile:
Ambulatory BP study (2022): The least squares mean difference between vibegron and placebo in daytime systolic BP was only 0.8 mmHg (90% CI: -0.9 to 2.5), with no significant differences in diastolic BP or heart rate 4
Elderly population analysis (2021): In patients ≥65 years, there were no significant differences in blood pressure or pulse rate between vibegron and placebo groups after 12 weeks 5
Men with BPH (2024): Among 1,105 men receiving α-blockers (which can cause orthostatic hypotension), vibegron showed similar adverse event rates to placebo, with hypertension being the most common cardiovascular event (9.0% vs 8.3% placebo) 6
Clinical Context: Distinguishing from Beta-Blockers
The provided guidelines extensively discuss hypotension as a side effect of beta-blockers (β1/β2 antagonists), particularly those with alpha-1 blocking properties 2, 3, 2. This is mechanistically opposite to vibegron:
- Beta-blockers (especially carvedilol): Can produce hypotension through vasodilation, typically within 24-48 hours of first dose, usually asymptomatic but may cause dizziness or lightheadedness 2, 3, 2
- Vibegron (β3-agonist): Selective for β3 receptors in bladder, does not affect vascular tone
Practical Implications
- No dose adjustment needed for patients with hypertension or those on antihypertensive medications
- No increased monitoring for hypotension is required when initiating vibegron
- The most common cardiovascular adverse event is hypertension (not hypotension), occurring in approximately 9% of patients, similar to placebo rates 6, 7
- Vibegron can be safely used in elderly patients and those with multiple cardiovascular comorbidities 5
Important Caveat
While vibegron does not cause hypotension, clinicians should be aware that hypertension was reported as an adverse event in clinical trials at rates of 8.8-9.2% 7. However, this rate was comparable to placebo groups and likely reflects the baseline prevalence of hypertension in the OAB population rather than a drug effect 4.